SPYRE THERAPEUTICS, INC.
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2021 | — | $83.9M | $15.1M |
| FY2022 | — | $50.3M | $34.9M |
| FY2023 | — | $184.0M | $188.9M |
| FY2024 | — | $517.8M | $89.4M |
| FY2025 | — | $715.2M | $85.7M |
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2021 | — | $83.9M | $15.1M |
| FY2022 | — | $50.3M | $34.9M |
| FY2023 | — | $184.0M | $188.9M |
| FY2024 | — | $517.8M | $89.4M |
| FY2025 | — | $715.2M | $85.7M |